M.D. Anderson Cancer Center: Carcinoma, Renal Cell trials

The registry lists 54 Carcinoma, Renal Cell studies with M.D. Anderson Cancer Center as lead sponsor. 9 are open to participants now and 19 have results posted.

Early Phase 1 3Phase 1 11Phase 2 38Phase 3 1No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell CarcinomaRecruitingNCT07564232Phase 1
• Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept StudyRecruitingNCT07187869Phase 1
• Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)RecruitingNCT07187778Phase 2
• Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)RecruitingNCT07023432Phase 2
• Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell CarcinomaRecruitingNCT06940518Phase 2
• Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell CarcinomaRecruitingNCT06053658Phase 2
• Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxRecruitingNCT05092373Phase 1
• A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesRecruitingNCT05048212Phase 2
• Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME TrialRecruitingNCT04693377Not applicable
• Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted AntibodiesTerminatedNCT04902040Phase 1/2Results posted
• Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary CarcinomaTerminatedNCT03274258Phase 2Results posted
• Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney CancerCompletedNCT03015740Phase 1/2Results posted
• Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are MetastaticActive, not recruitingNCT02721732Phase 2Results posted
• Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)CompletedNCT02060370Phase 2Results posted
• Contrast Enhanced Intraoperative Ultrasound for Detection and Characterization of Renal Mass Undergoing Open Partial NephrectomyCompletedNCT01894607Not applicableResults posted
• Carfilzomib in Refractory Renal Cell Carcinoma (RCC)CompletedNCT01775930Phase 2Results posted
• A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation TherapyCompletedNCT01624220Not applicableResults posted
• Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)CompletedNCT01392183Phase 2Results posted
• Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)CompletedNCT01263769Phase 2Results posted
• Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell CarcinomaTerminatedNCT01185366Phase 2Results posted
• Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell CarcinomaTerminatedNCT00561912Phase 2Results posted
• Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell CarcinomaCompletedNCT00496587Phase 2Results posted
• Pemetrexed Plus Gemcitabine in Renal Cell CancerTerminatedNCT00491075Phase 2Results posted
• Zoledronate With Atorvastatin in Renal Cell CarcinomaCompletedNCT00490698Phase 2Results posted
• Sunitinib Malate in Patients With Non-Clear Cell Renal Cell CancerCompletedNCT00465179Phase 2Results posted
• Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT00429026Phase 2Results posted
• Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to FollowTerminatedNCT00330564Phase 2Results posted
• Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell CarcinomaCompletedNCT00113217Phase 2Results posted
• Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain MetastasesWithdrawnNCT07011849Phase 2
• A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)Active, not recruitingNCT06708949Phase 2
• Impact of Perioperative Anesthetic Management on Renal Cancer Progression.WithdrawnNCT06536244
• A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)Active, not recruitingNCT06284564Phase 2
• Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCCSuspendedNCT05663710Phase 1/2
• Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.Active, not recruitingNCT05501054Phase 1/2
• Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell CancerActive, not recruitingNCT05012371Phase 2
• Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell CancerTerminatedNCT04904302Phase 2
• MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK TrialWithdrawnNCT04580836Phase 2
• DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell CancersActive, not recruitingNCT04388852Phase 1
• Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney CancerCompletedNCT03587662Phase 2
• Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell CarcinomaSuspendedNCT03575611Phase 2
• Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell CarcinomaActive, not recruitingNCT03541902Phase 2
• Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney CancerCompletedNCT03473730Early Phase 1
• Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal CordActive, not recruitingNCT02713269Phase 2
• Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney CancerCompletedNCT02626130Early Phase 1
• Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesTerminatedNCT02419495Phase 1
• Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by SurgeryActive, not recruitingNCT02210117Early Phase 1
• Aerosolized Aldesleukin in Treating Patients With Lung MetastasesActive, not recruitingNCT01590069Phase 1/2
• The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)Status unknownNCT01447199
• Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) ScrambleActive, not recruitingNCT01224288Phase 3
• Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START TrialActive, not recruitingNCT01217931Phase 2
• Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)CompletedNCT01122615Phase 1
• Follow-up After Metastasectomy in Patients With Kidney CancerActive, not recruitingNCT00918775Phase 2
• Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)Active, not recruitingNCT00715442Phase 2
• Biobehavioral Effects of Emotional Expression in CancerCompletedNCT00505310Not applicable